Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Recruitment status was: Active, not recruiting
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Drug: mitomycin C
Drug: vinorelbine tartrate
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer|
|Study Start Date:||September 1998|
- Determine the response rate and duration of response to mitomycin, vinorelbine, and cisplatin plus tretinoin in patients with stage IIIB or IV non-small cell lung cancer.
- Determine the toxicity of this treatment regimen in these patients.
- Determine survival of these patients with this treatment regimen.
OUTLINE: Patients receive tretinoin orally twice daily for 4 days starting days 1 and 8; cisplatin IV over 2 hours and vinorelbine IV on days 1 and 8; and mitomycin IV (courses 1 and 3) on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: At total of 15-46 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005825
|United States, California|
|Rajendra Prasad M.D., Inc.|
|Lakewood, California, United States, 90712|
|Study Chair:||Raghu Nandan, MD||Raghu Nandan, M.D., Inc|